Loading
A phase 3 trial of bevacizumab in lung cancer, run by Sun Yat-sen University, now recruiting.
Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases is a phase 3, randomised interventional study registered as NCT07481786 by Sun Yat-sen University, with a registry enrolment figure of 220 participants, started 2026-03-20 and due to reach its primary completion in 2029-09-15. Interventions recorded: FSRT; HA-WBRT-SIB; Bevacizumab. Conditions listed: Lung Adenocarcinoma; Brain Metastases; Radiotherapy, Intensity-Modulated; Bevacizumab; Whole-Brain Radiotherapy. Primary outcome: Intracranial Progression-Free Survival (IPFS); Neurocognitive Function failure. Lung eligibility wording from the registry: "* Pathologically confirmed non-squamous non-small cell lung cancer (adenocarcinoma)". Sites: China. No results are recorded here; the registry entry is the source.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.